Montelukast vs Pembrolizumab
Montelukast vs Pembrolizumab: Overview
This comparison examines the pharmacological differences between Montelukast and Pembrolizumab.
Mechanism of Action
Montelukast: Selective leukotriene D4 receptor antagonist.
Pembrolizumab: Anti-PD-1 monoclonal antibody restoring anti-tumor immunity.
Pharmacokinetics
Half-life: Montelukast — 2.7-5.5 hours; Pembrolizumab — 26 days.
Chemical Properties
Molecular Formula: Montelukast — C35H36ClNO3S.
Molecular Weight: Montelukast — 586.1800 g/mol.
Type: Montelukast — Small molecule; Pembrolizumab — Antibody.